In this episode, host Shikha Jain, MD, speaks with Edith Perez, MD, about equity initiatives in health care organizations, the evolution of precision oncology and more.

• Welcome to another exciting episode of Oncology Overdrive :14
• About Perez :21
• The interview 1:03
• Tell me about yourself and how you got to where you are today 1:20
• About Perez's involvement in many kinds of work in oncology 4:45
• How did you get involved in your equity and philanthropy work, and what do you do? 5:44
• Do you feel like your work has been changed or modified over the last couple of years with the pandemic, or did knowledge of the problem already exist? 8:30
• What changes do you hope to see in the next 5 to 10 years? Long-term, what are the biggest issues that we need to work on improving? 10:12
• What does Bolt Biotherapeutics do, and what are their missions and initiatives? 12:26
• What do you see happening with Bolt and this kind of technology and therapy over the next 5 to 10 years? 15:01
• Jain and Perez discuss the evolution of precision oncology over the years 16:06
• As a woman in this field, how did you navigate your path into these leadership roles? 19:17
• If clinicians or trainees were interested in getting into the immuno-oncology industry space, how would you recommend they navigate a path? 22:04
• Was the transition from industry to a smaller company scary, or did you know this is what you wanted to do next with your life? 24:06
• Have you learned your leadership skills, or were they something you were taught? … Is the training more experience/on-the-job, or is it something you seek out? 26:03
• If someone could only listen to the last 2 minutes of this episode, what would you want them to take away? 30:03
• How to contact Perez 30:51
• Thanks for listening 31:36

Edith A. Perez, M.D., is chief medical officer of Bolt Biotherapeutics and an internationally recognized translational researcher and cancer specialist.

We'd love to hear from you! Send your comments/questions to Dr. Jain at [email protected]. Follow us on Twitter @HemOncToday and @ShikhaJainMD. Perez can be reached on LinkedIn or via email [email protected].

Disclosures: Jain reports no relevant financial disclosures. Perez reports employment with Bolt Biotherapeutics and Genentech, leadership at Bolt Biotherapeutics, stock and other ownership interests in Genentech/Roche, and a consulting or advisory role at Daiichi Sankyo, Puma Biotechnology, and Seattle Genetics.